All posts by imreal

New Book, “The Simple Guide to a Successful You,” Reveals How a Human Trafficking Survivor Took Control of Her Life and Found Her Dream Career


Sarah Lebel

Sarah Lebel

Especially in light of more people acknowledging their trauma with initiatives like the Me Too movement, I believe that there is a gap in resources for people like me, and the millions of other survivors, that are wondering ‘what’s next?’ in their life journey.

With her first book, “The Simple Guide to a Successful You: Navigating Your Career After Life Gets Messy,” author Sarah Lebel delivers her own heart wrenching true story of surviving human trafficking and the steps she took to get control of her life and ultimately find her dream career.

“The Simple Guide to a Successful You” pragmatically shares a variety of her own experiences as a human trafficking survivor navigating the workplace, and the tactics she used to begin discovering her passions and climbing the career ladder. Hope and optimism are prevalent, but it does not ignore the harsh reality that life can get messy for anyone.

“As a survivor of human trafficking that is now living a life that I never dreamed I could have, I feel it is my duty to share my own experience with other people. Especially in light of more people acknowledging their trauma with initiatives like the Me Too movement, I believe that there is a gap in resources for people like me, and the millions of other survivors, that are wondering ‘what’s next?’ in their life journey,” Lebel says. “Trauma can happen to anyone. My hope is that this book shines a light on the fact that no matter what has happened in your life, there is hope.”

“Each of the steps that I outlined in this book are based on my own experience, and even if just one reader is able to carve a passion-filled life path, that’s all that matters,” Lebel said. “If it motivates someone to take action and as a result a life is renewed, or a family is healed, then mission accomplished.”

“The Simple Guide to a Successful You” is now available in ebook and print versions at Amazon.

About the Author

Sarah Lebel is a survivor and advocate in the fight against human trafficking. As a result of her personal experiences, she founded the non-profit But What Is Next, which supports trauma survivors in creating a fulfilling and stable life by connecting them with resources to carve out their career path, and the financial support to make it happen.

Share article on social media or email:

Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL, Upcoming Webinar Hosted by Xtalks


The speaker will discuss how single-cell DNA sequencing allowed high-sensitivity detection of driver mutations that bulk next-generation sequencing didn’t call, identifying minute subclones at the time of CLL diagnosis which were dormant for six to 19 years until rapid expansion at transformation.

Richter’s transformation (RT) is a rare condition in patients with chronic lymphocytic leukemia (CLL) which transforms into a much more aggressive form of B cell lymphoma, conferring a poor prognosis. The mechanisms and molecular changes that drive RT remain largely unknown. In this webinar, the featured speaker, Dr. Ferran Nadeu, will discuss their research study recently published in Nature Medicine where they applied single-cell DNA sequencing (scDNA-seq) to resolve clonal heterogeneity and detect rare pre-existing mutations associated with disease transformation.

To identify the genetic driver mutations and evolutionary histories over the disease course, Dr. Nadeu’s lab first sequenced the whole genome of 54 longitudinal samples covering up to 19 years of disease course in 19 cases of CLL developing RT. They then performed single-cell DNA sequencing using the Tapestri Platform and the 32-gene CLL Catalog Panel from Mission Bio on 16 longitudinal samples of four cases to validate these evolutionary histories of RT, and to track early driver mutations over the disease course.

The speaker will discuss how single-cell DNA sequencing allowed high-sensitivity detection of driver mutations that bulk next-generation sequencing didn’t call, identifying minute subclones at the time of CLL diagnosis which were dormant for six to 19 years until rapid expansion at transformation. He will also overview the findings from the study that suggest that CLL evolution to RT is driven by pre-existing subclones generated before diagnosis and that early intervention to eradicate the dormant RT subclones may prevent the future development of this lethal complication of CLL, uncovering potential therapeutic targets for RT.

Register to learn about unraveling clonal heterogeneity & progression to Richter’s transformation in chronic lymphocytic leukemia with single-cell DNA sequencing.

Join Ferran Nadeu, Postdoctoral Researcher, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, for the live webinar on Monday, November 7, 2022, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies? Upcoming Webinar Hosted by Xtalks


The webinar will explore how humanized mouse models allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies and other drugs.

In this webinar, the featured speakers will describe humanized immune system mouse models and how they can support preclinical drug development. The webinar will explore how humanized mouse models allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies and other drugs.

First, speaker Sebastien Tabruyn will talk about the advantages of the humanized mouse models with human immune system (HIS) for immunology and oncology research and preclinical study techniques.

Next, speaker Wout de Wispelaere will present an application of humanized mice in the study of aggressive tumors: uterine leiomyosarcomas (uLMS) and a pathway to initiate an anti-tumor adaptive immune response.

Register to learn how humanized mouse models can be used to study cancer and the development of new immune-targeted therapies.

Join Wout de Wispelaere, PhD Researcher, University of KU Leuven; and Sebastien Tabruyn, PhD, Chief Scientific Officer, General Manager, TransCure bioServices, for the live webinar on Tuesday, November 8, 2022, 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

HMP Global’s 2022 Cocaine, Meth & Stimulant Summit addresses surge in stimulant misuse, illicit drug use and addiction


Stimulant Summit logo

The Cocaine, Meth & Stimulant Summit will offer front-line professionals fighting this crisis the strategies and best practices needed to address stimulant misuse in their communities.

America’s addiction and overdose epidemic is reaching record levels, with stimulants becoming increasingly prevalent throughout the country.

Organized by HMP Global, the omnichannel leader in healthcare events and education, the 2022 Cocaine, Meth & Stimulant Summit will offer front-line healthcare and law enforcement professionals fighting this crisis the strategies and best practices needed to address stimulant misuse in their communities.

The Summit will be held virtually November 2-4, providing top quality training and education for clinical, law enforcement, and public health professionals. Now in its fifth year, the 2022 agenda features leading experts at the national, state, and local levels working to address the surge in illicit drug use and addiction in the United States.

“The opioid epidemic made headlines while the stimulant crisis loomed closely behind,” said Doug Edwards, Senior Vice President at HMP Global and Director of the Psychiatry & Behavioral Health Learning Network. “It is estimated that 5 million Americans misuse prescription stimulants, and more than 2 million American teens and adults reported past-year methamphetamine use. Compounding this issue, counterfeit prescription pills are being laced with illicit drugs in alarming amounts. It is urgent that we work together to find solutions. We cannot afford to lose more ground, for more lives to be lost.”

The Summit opening session features a documentary style video about the border community of Yuma, Ariz., “Perspectives on the Stimulant Crisis and the Impact on One Community.” Considerable amounts of fentanyl and other illicit substances come into the U.S. through its southern border. This documentary shows the devastating impact for families, schools, and communities, and how stakeholders throughout Yuma County are working together and making progress in addressing this crisis.

Other key presentations include:


  • The National Stimulant Use Landscape: Reviewing Data and Trends
  • Stimulant Use Disorder Response and Treatments — Insight from the National Institute on Drug Abuse
  • At the Intersection of Methamphetamine and Fentanyl: Trends in Use Patterns, Morbidity and Mortality in the U.S. Stimulant/Opioid Epidemic
  • Federal Government Voices — Policy Updates
  • Addressing Methamphetamine as an Emerging Threat: Overview of Federal Response Plan
  • Customizing Stimulant Use Responses Based on Community Unique Needs and Location
  • Takeaway Messages on the Stimulant Crisis from State Government Officials

Led by multi-disciplinary experts from across the nation, the Summit provides an extensive educational experience for professionals on the front lines of this rising epidemic. Featured speakers include:

  • Rahul Gupta, MD, Director, Office of National Drug Control Policy
  • Robert Califf, MD, Commissioner, Food and Drugs Administration
  • Nora Volkow, MD, Director, National Institute on Drug Abuse
  • Debra Houry, MD, Acting Principal Deputy Director, Centers for Disease Control and Prevention; Director, National Center for Injury Prevention and Control
  • Jennifer Smith, Secretary, Pennsylvania Department of Drug and Alcohol Programs
  • John Eadie, MPA, Coordinator, Public Health and Prescription Drug Monitoring Program Project, National Emerging Threats Initiative, A National HIDTA Initiative
  • Daniel Ciccarone, MD, Professor of Family and Community Medicine, University of California, San Francisco

The Cocaine, Meth & Stimulant Summit is designed and accredited for professionals in the fields of addiction, behavioral, and mental health, and law enforcement and public safety. It brings together law enforcement and treatment providers to discuss strategies to prevent stimulant misuse, provide access to treatment, and ensure that stimulants are part of larger social discussions about addressing drug use.

The Summit is a sister event to the Rx and Illicit Drug Summit, the largest national collaboration of professionals from local, state, and federal agencies, business, academia, treatment providers, and allied communities impacted by prescription drug misuse and heroin use. Rx Summit is the leading event for decision-makers and allied professionals working to address this public health emergency.

For more information, sponsorship opportunities, or to register for the Cocaine, Meth & Stimulant Summit, visit stimulantsummit.com.

ABOUT HMP GLOBAL 

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Share article on social media or email:

IntellectAbility and NPACE Partner to Bring Vital IDD Healthcare Education to Clinicians to Reduce Health Disparities for People With IDD


News Image

IntellectAbility’s Curriculum in IDD Healthcare teaches the fundamentals of IDD healthcare, providing StationMD clinicians with pertinent, practical information which is critical to the provision of IDD competent telehealth supports

According to the National Council on Disability Health Equity Framework for People with Disabilities,¹ people with IDD face significant, preventable health disparities. In a call to action to improve the healthcare provided to people with IDD, the framework recommends comprehensive disability clinical-care curricula be required for nursing and healthcare professionals. The goal is to empower healthcare professionals to better understand the healthcare needs of people with IDD. To respond to this need, IntellectAbility and NPACE are partnering to give healthcare providers practical and immediately usable clinical knowledge to improve healthcare for people with IDD, using the online Curriculum in IDD Healthcare (CIDDH).

People with IDD present unique health challenges that practicing physicians, nurse practitioners, physician assistants, nurses, and other healthcare professionals are often unprepared to address. Implementing the Curriculum in IDD Healthcare has shown to be effective in improving IDD clinical competency among healthcare providers and students. Feedback from clinicians and students who took the course shows that the CIDDH is doing precisely that.

“IntellectAbility’s Curriculum in IDD Healthcare teaches the fundamentals of IDD healthcare, providing StationMD clinicians with pertinent, practical information which is critical to the provision of IDD competent telehealth supports”, shares Dr. Maulik Trivedi, Chief Strategy Officer of StationMD. “That is why we at Station MD use the CIDDH to educate our physicians and nurse practitioners.”

IntellectAbility is partnering with NPACE to make the curriculum more widely available to Nurse Practitioners who encounter people with IDD on a regular basis and, as a result, need access to pertinent, practical information designed to enhance their IDD healthcare competence.

This online course is specifically created for clinicians, including physicians, nurse practitioners, physician assistants, dentists, nurses, allied health professionals, and students of these disciplines. It was written and delivered by Craig Escudé, MD, FAAFP, FAADM, with over 20 years of experience providing medical care for people with IDD and teaching others about this area of medicine on a national level.

“We are excited to partner with IntellectAbility to provide IDD healthcare-specific education and training to nurse practitioners and other clinicians. Through a dedicated curriculum in IDD healthcare, we believe we can work together to overcome health disparities,” states Josh Plotkin, COO at NPACE.

Eliminating barriers to health equity allows people with IDD to participate fully in all aspects of community life, realize their dreams, and mitigate the impacts of poor health and the burden of chronic disease. This mission has led these organizations to lead the way in improved training and educational opportunities for healthcare providers. To learn more, visit http://www.ReplacingRisk.com.

About IntellectAbility

IntellectAbility provides tools and training to agencies, governmental entities, and supporters of people with intellectual and developmental disabilities to foster early recognition and mitigation of health risks, thereby improving health and wellness. One such tool is the Health Risk Screening Tool (HRST), of which they are the sole developer, producer, and distributor. The web-based HRST is the most widely used and validated health risk screening instrument for people with intellectual and developmental disabilities. IntellectAbility also provides numerous health-related and person-centered service trainings for supporters of people with IDD. With unrelenting focus, IntellectAbility works to fulfill its mission of improving health and quality of life for people with intellectual and developmental disabilities and other at-risk populations. For more information, visit http://www.ReplacingRisk.com.

Reference:

1. “Health Equity Framework for People with Disabilities.” Released February 2022, Updated August 2022. National Council on Disability.https://ncd.gov/sites/default/files/NCD_Health_Equity_Framework.pdf

Share article on social media or email:

Hospitals Seek High-Tech Solutions to Meet Telehealth Demands


News Image

Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology.

In 2020, the COVID-19 pandemic dramatically changed hospital operations. As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.(1) Patients and providers relied on a patchwork of videoconferencing systems, patient portals, and rudimentary home health equipment to manage non-emergency care. “Value-based care means flexibility in clinical capability,” says The Virtual Telemetry Company, InfoBionic, CEO Stuart Long. “Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology.”

The pandemic revealed two major findings about telehealth. 1) First, patients appreciate the convenience of home access to medical information and communication with providers. 2) Second, the technology for remote healthcare is insufficient for the needs of patients.

Providers and healthcare facilities are racing to upgrade systems to use telehealth more effectively in the near future. Remote telemetry for monitoring patients’ vital functions is a top technology priority. Industry analysts predict that the market for remote cardiac monitoring devices will grow from $6.48 billion to $11.49 billion annually by 2030.(2) Companies like InfoBionic are stepping up to provide the next generation of remote telemetry tools.

Telemetry refers to any system that allows medical staff to monitor patients without being present in the room. Hospital systems regularly use telemetry to monitor patients.

Patients in an ICU, for example, might be one of the most sophisticated stationary cardiac monitors that are remotely monitored 24/7 and incorporate that several life critical vital signs. In contrast, staff would use different telemetry systems designed to monitor patients with less acute needs, but the patient would still occupy a designated step-down or progressive care telemetry bed with continuous monitoring. These latter systems monitor fewer vital signs and are not intended for severely ill or the highest acuity patients. Further, they can be limited in their portability and often are confined to just these areas of the hospital, thereby making it difficult to transport patients to non-telemetry areas of the hospital like radiology or cardiology.

Hospitals have a limited number of beds that can accommodate the high- and mid-level telemetry that patients need. As a result, patients may remain in the ICU longer than necessary due to a lack of step-down beds. For many patients, monitoring is the only service they need from a hospital.

Advanced mobile telemetry would allow hospitals to accommodate patient needs in any bed.

InfoBionic’s MoMe™ ARC Platform* is being designed to be the first platform on the market to deliver that level of acuity, agility, and adaptability in virtual cardiac care. “We envisioned an entirely portable and adaptable system for cardiac monitoring,” says Long. “The monitors themselves are not tethered to a single area of a facility, allowing uninterrupted use even when a patient moves between departments.

The next generation MoMe* is being designed specifically for hospital telemetry to provide a step-down level of telemetry for any bed or location that would need an easy-to-deploy mobile telemetry monitor. Further, it builds on our core expertise to enable a seamless hospital-to-home patient transition where continuous monitoring from real-time to near real-time is essential for meeting the demands of virtual care monitoring.

For more information about InfoBionic, visit their website at https://infobionic.com/.

*This product has not been approved by the FDA for sale in the US.

About InfoBionic

InfoBionic’s digital technology has transformed the clinical efficiency and economics of cardiac remote patient monitoring. The company’s MoMe™ ARC platform has removed the roadblocks hindering remote diagnosis and clinical decision-making. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology. More recently, working side by side with the healthcare and medical technology communities, including its own competitors, InfoBionic has developed MoMe® Now, the first virtual telemetry system for high-acuity patients in remote, virtual, or hospital-at-home care environments. Visit https://InfoBionic.com/

References:

1. Morbidity and Mortality Weekly Report (MMWR). Trends in Use of Telehealth Among Health Centers During the COVID-19 Pandemic — United States, June 26–November 6, 2020. February 2021.

2. Acumen Research and Consulting. Cardiac Arrhythmia Monitoring Devices Market Analysis – Global Industry Size, Share, Trends and Forecast 2022 – 2030. June 2022.

Share article on social media or email:

Public Voting Now Open for MedVet’s Shelter Surprise to Award Funds to Local Shelters


MedVet Shelter Surprise Voting is Live

MedVet Shelter Surprise Voting is Live

Many shelters and rescues have a great need for support, so we are excited to be able to raise awareness for them while also offering some funds to cover some of their expenses.

Voting is now open for MedVet’s Shelter Surprise contest which will award three deserving shelters cash prizes to support the important work they do to save pets. Out of hundreds of nominations, 10 animal shelter and rescue organizations were chosen, and it’s now up to the public to decide which organization will receive cash prizes.    

“We are honored to collaborate with many animal shelters and rescues that are working to save pets and place them with loving families,” said Dr. Linda Lehmkuhl, Chief Executive Officer of MedVet. “These facilities are typically under-resourced for the important work they are doing. Many shelters and rescues have a great need for support, so we are excited to be able to raise awareness for them while also offering some funds to cover some of their expenses.”

Throughout September and October, individuals nominated deserving shelters and rescues for the contest, and now the public is invited to cast their votes for the organization they would like to see win the top prize. Voting is open from Oct. 24-Nov. 4. The organization with the most votes will receive $2,000, the second-place organization will receive $1,250, and a third winner will receive $500. Winners will be announced during National Animal Shelter and Rescue Appreciation Week, which takes place Nov. 6-13.

The 10 finalist organizations are:

  • Asheville Humane Society in Asheville, NC
  • Cincinnati Animal CARE in Cincinnati, OH
  • Dallas Dog RRR in Dallas, TX
  • For the Love of Cats in Commerce, MI
  • Meridian Canine Rescue in Meridian, ID
  • Northshore Humane Society in Covington, LA
  • Paws Up 4 Rescue in Joliet, IL
  • Project Precious Rescue in Stamford, CT
  • Stop the Suffering in Columbus, OH
  • West Valley City Animal Shelter in West Valley, UT

Find more information about the contest and vote for your favorite shelter or rescue here.

About MedVet:

MedVet is the leading veterinarian owned and led family of specialty and emergency hospitals and urgent cares dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 30 years, MedVet’s empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. To learn more about MedVet and its mission of Leading Specialty Healthcare for Pets, visit medvet.com. 

###

Share article on social media or email:

Allegheny Health Network Cardiovascular Institute First in Pittsburgh to Implant Groundbreaking Neuromodulation Device as Alternative Therapy for Heart Failure Patients


News Image

“Today’s announcement is an exciting milestone for our heart failure patients…it provides another novel approach that is proven to minimize heart failure’s damaging effects and restore a patient’s overall quality of life,” — Dr. Satish Muluk, director of AHN Division of Vascular Surgery.

Vascular surgeons from Allegheny General Hospital (AGH) Cardiovascular Institute, the flagship academic medical center of Allegheny Health Network (AHN), announced today the first successful implant of a new neuromodulation device used as an alternative therapy for patients with progressive heart failure (HF) who may not be receiving adequate relief from medical therapies.

The device, titled Barostim™ Baroreflex Activation Therapy, is from Minneapolis-based med tech company CVRx and is the world’s first FDA-approved HF device to use manipulation of the nervous system to reinvigorate the heart and improve its function.

The implant procedure took place in early September under the clinical direction of Satish Muluk, MD, vascular surgeon and director of AHN Division of Vascular Surgery and Srinivas Murali, MD, heart failure specialist and System Chairman of the AHN Department of Cardiovascular Medicine.

“Heart failure is a condition that causes the muscle in the heart wall to slowly weaken and enlarge, preventing the heart from pumping enough oxygenated blood throughout the body,” explained Dr. Muluk. “The symptoms of heart failure are often progressive, and the condition can worsen on medical therapy alone. Today’s announcement is an exciting milestone for our heart failure patients throughout western Pennsylvania as it provides another novel approach that is proven to minimize heart failure’s damaging effects and restore a patient’s overall quality of life.”

According to the American Heart Association, heart failure is one of the most common reasons people over the age of 65 are admitted to the hospital. It’s a chronic condition with symptoms ranging from shortness of breath and extreme fatigue to lightheadedness and fluid retention, among others.

Approximately six million Americans are currently living with heart failure and research indicates the number of individuals living with cardiovascular disease will likely surge to 12.9 million by 2060. From a local perspective, the leading cause of death in Allegheny County is heart disease, above cancer, accidental injuries and cerebrovascular disease. Furthermore, heart disease in the Greater Pittsburgh population tracks notably higher than the state average, according to the PA Department of Health.

To date, the prescribed course of management involves a multidisciplinary approach involving medical therapies, lifestyle enhancements and surgical interventions ranging from minimally invasive implantations of pacemakers and defibrillators to more aggressive management paths of open-heart surgery to implant a left-ventricular assist device (LVAD) or heart transplantation.

Unlike other HF treatment options, Barostim does not require any hardware implantation in the heart but uses an electrode that’s placed on the patient’s carotid artery within the neck during a minimally-invasive outpatient procedure. The electrode provides continuous electrical stimulation to the body’s carotid baroreceptors, the body’s natural mechanism that regulates cardiovascular function.

Barostim’s stimulation triggers both the body’s sympathetic (“fight or flight” response) and parasympathetic (“rest and digest” response) nervous systems to create a unique balance that in turn better regulates the function of a patient’s heart, kidney and vascular system.

“Unlike a pacemaker, Barostim stimulates the nervous system to address a neuro-hormonal imbalance which is the root cause of heart failure. In many instances, the baroreceptors in heart failure patients have lost their vigor and so this device kick starts the nervous system into high gear restoring neuro-hormonal balance which in turn improves cardiovascular performance,” explained Dr. Murali. “Patients can go home on the same day as the procedure, and our team gradually adjusts the output of the device over the next few weeks to specifically tailor electrical stimulation to achieve optimal improvement of the patient’s symptoms.”

The Journal of the American College of Cardiology published a study (https://doi.org/10.1016/j.jacc.2020.05.015) from cardiovascular researchers demonstrating the overall effectiveness of Barostim in a controlled patient population living with heart failure and a reduced ejection fraction. Four patient cohorts were created from 408 randomized patients with select groups receiving baroreflex activation therapy and medical management or solely optimal medical management. Results showed Barostim patients were able to walk about 65 yards further in six minutes and had three times greater improvement in quality-of-life scores when compared to patients on medications alone.

“Providing innovative treatment options for heart failure patients is an important endeavor and we congratulate Drs. Muluk and Murali and Allegheny General Hospital on a successful Barostim implantation,” said Nadim Yared, President and CEO of CVRx. “We look forward to continuing to support Allegheny General Hospital to help more patients live fuller lives.”

For more information or to make an appointment with AHN Cardiovascular Institute, visit ahn.org.

###

About the Allegheny Health Network:

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, multiple employed physician organizations, home and community based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 21,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Share article on social media or email:

Santé Center for Healing’s Offers 3 Collegiate Scholarships


We offer these collegiate scholarships with the desire to assist individuals who are working to further their education. Helping individuals in recovery from addiction and/or specifically wanting to pursue a degree in these important fields aligns with Santé’s core values.

Three scholarship awards will benefit collegiate students wishing to further and advance their education, whether they are in recovery and/or pursuing careers in the mental and behavioral health fields.

“We offer these collegiate scholarships with the desire to assist individuals who are working to further their education. Helping individuals in recovery from addiction and/or specifically wanting to pursue a degree in these important fields aligns with Santé’s core values,” says CEO Sam Slaton, MEd, LPC-S, MBA, MHSM. “Providing assistance to those entering this field is a privilege.”

The award amount for each is $500 and recognizes three of Santé’s legacy makers:

  • The Rip Corley & Santé Center for Healing Scholarship in memory of Santé’s co-founder Rip Corley, LMSW, RN. This will go to an individual in recovery (2 year minimum) from addiction who has completed at least one year in college and pursuing an undergraduate degree from an accredited college and/or university.
  • The Dr. Deb Corley & Santé Center for Healing Scholarship in honor of Santé’s co-founder/co-owner M. Deborah Corley, PhD. This will go to an individual pursuing a graduate degree towards work in the mental and behavioral health field.
  • The Sam Slaton & Santé Center for Healing Scholarship in celebration of Santé’s CEO Sam Slaton, MEd, LPC-S, MBA, MHSM years of leadership. This will go to an individual pursuing a graduate degree towards health care management.

Submission and Award Details

Submission period: September 1, 2022 – December 5, 2022

Award Announcement: December 9, 2022

Award Date: December 21, 2022

In 2020, 73.8 million Americans (adults aged 18 or older) had a mental illness and/or substance use disorder in the past year.¹ It is vital to have qualified individuals in the fields of mental and behavioral health and health care management.

For more scholarship insights and eligibility requirements, click here.

About Santé Center for Healing: Santé Center for Healing provides integrity-driven, evidence-based, and personalized long-term recovery for those suffering from substance use disorders, mental health, trauma, problematic sexual behavior, co-occurring disordered eating and other compulsive behaviors. Santé was founded in 1996 and is celebrating more than 26 years of service. For more information, visit http://www.santecenter.com.

1. Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/

Share article on social media or email:

Ideal Option and Brick House Recovery to Co-Host Open House


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction, and Brick House Recovery will co-host an open house in Coeur d’Alene on Friday, November 4, at 3918 N Schreiber Way.

“We appreciate the collaboration with Ideal Option to create synergy and address the opioid crisis, addiction and mental health challenges facing the Idaho Panhandle,” said Jason Coombs, CEO of Brick House Recovery. “Our mission is to provide exceptional and effective treatment for adults struggling with substance abuse and co-occurring disorders.”

Recipient of the 2022 Idaho’s Best in Mental Wellness award, Brick House Recovery offers a higher power-based family-centered approach to treatment and long-term recovery.

“At Ideal Option, we’re proud to embrace and collaborate with all providers of recovery services in the communities where we operate,” said Tim Kilgallon, CEO of Ideal Option. “Brick House Recovery is one of the best and most well-respected of those providers in Idaho, so we are thrilled to be sharing our space with them. We hope that this collaboration will encourage more people to take advantage of our combined services available in Coeur d’Alene.”

On Friday, November 4, from both 11 a.m. to 2 p.m. and 4 p.m. to 7p.m., all members of the community are invited to drop by the new clinic in Coeur d’Alene located at 3918 N Schreiber Way. A ribbon-cutting ceremony with the Coeur d’Alene Regional Chamber will take place at noon.

During the open house, attendees can tour the facility, pick up printed materials, meet Ideal Option and Brick House Recovery staff, enjoy refreshments, and grab one of 50 autographed copies of the #1 Amazon Best Seller: “Unhooked: How to Help an Addicted Loved One Recover,” by Jason Coombs.

For questions about this event, email Senior Marketing Manager Olivia Roe at oliviaroe@idealoption.net.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 60,000 patients through a network of over 80 office-based medication-assisted treatment (MAT) clinics across 10 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

About Brick House Recovery

For more information about Brick House Recovery, please contact Jason Coombs at jason@brickhouserecovery.com or visit their website at http://www.brickhouserecovery.com.

Share article on social media or email: